

**FOR IMMEDIATE RELEASE**

February 2005

Stuart G. Gordon, Ph.D., Director  
Office of Technology Transfer and Commercialization  
CSU San Bernardino  
5500 University Parkway  
San Bernardino, CA 92407-2397  
Phone: (909) 880-7766  
FAX: (909) 880-7450  
email: sgordon@csusb.edu  
Website: ottc.csusb.edu

**California State University San Bernardino, Office of Technology Transfer and Commercialization Announce Successful Clinical Trial Results From Portfolio Company**

SAN BERNARDINO, California. The California State University- San Bernardino, Office of Technology Transfer and Commercialization (CSUSB-OTTC) and its Center for Commercialization of Advanced Technology (CCAT) program under the direction of Stuart Gordon, Ph.D announced today that a medical break through for the prevention of hearing loss has been confirmed by one of its portfolio companies, American BioHealth Group (ABG). The confirmation comes as the positive result of an Instructional Review Board approved, double blinded, placebo controlled, 550+ patient clinical trial conducted by the Naval Medical Center San Diego. This recently completed clinical trial provided objective evidence that a novel compound, protect by a patent issued to the US Navy, is effective in helping to prevent hearing loss from loud noise exposure (acoustic trauma). The study concluded that a reduction in permanent hearing loss was realized when compared to the placebo. For the first time millions of individuals will have available a safe and clinically proven capsule, without a prescription, that can help prevent the debilitating effects of acoustic trauma. ABG is commercializing the compound under the name "The Hearing Pill™" and is available at [www.thehearingpill.com](http://www.thehearingpill.com).

Several statistics clearly demonstrate the magnitude of hearing loss problems caused by acoustic trauma: According to the Center for Disease Control, acoustic trauma causes reduced hearing capacity for 39 million Americans annually and costs the nation billions of dollars per year. The National Institute of Occupational Health and Safety cites that at present exposure limits, one in four Americans will develop a permanent hearing loss as a result of their occupational exposure to noise hazards. Each year the DoD spends \$300 million on hearing loss compensation as reported by the Deputy Under Secretary of Defense, Science and Technology), while the Air Force Research Laboratory states that 22,000 new hearing loss claims are filed annually for the Navy, Marine Corps and Air Force and the Office of Naval Research says that noise induced hearing problems costs the Navy some \$69 million dollars a year. Finally, according to the National Institute of Hearing, sensorineural hearing loss is one of the most prevalent disabling conditions in the United States. It can harm an individual's physical, cognitive, behavioral, and social function and is caused by a problem in the cochlea or the auditory nerve, parts of the ear that help sound impulses reach the brain.

Dr. Gordon states, "We have been following, with great interest, the development of this technology for some time because an effective means of addressing acoustic trauma will be of substantial importance to the military and will have important benefits to the public. As a result of American BioHealth Group's management team proven ability to execute a well thought out business plan, we invested funds and resources to help advance this important medical technology. The collaboration between CCAT and ABG is a textbook example where academia and private enterprise pooled resources and synergies to deliver a paradigm changing medical solution. This is just the beginning of several exciting announcements that will come from our two organizations."

American BioHealth Group holds the exclusive license to commercialize this compound, and others, that address related hearing disorders. David Karlman, Chairman and Chief Executive Officer of American BioHealth Group, comments "Strong, trusting partnerships are a foundational belief in our company. The relationship ABG has with CCAT comes through continued focus on our business and clinical goals. Certainly the CCAT funds contributed by CSUSB-OTTC are deeply appreciated and it is also the non-balance sheet contributions that played an important role to this success story. Dr. Gordon, along with his talented staff, continues to offer valuable industry contacts, clinical advice and a never-ending belief in ABG. These and other contributions acted as an accelerator for this successful development."